CL2009000573A1 - Composicion farmaceutica inyectable intraocular en forma de suspension acuosa que no contiene preservante, que consiste de acetonido de triamcinolona, carboximetilcelulosa de sodio, 0,002-0,02% de polisorbato 80, cloruros para ajustar la tonicidad, agente tamponante, agua y agente de ajuste de ph; uso para tratar el ojo. - Google Patents

Composicion farmaceutica inyectable intraocular en forma de suspension acuosa que no contiene preservante, que consiste de acetonido de triamcinolona, carboximetilcelulosa de sodio, 0,002-0,02% de polisorbato 80, cloruros para ajustar la tonicidad, agente tamponante, agua y agente de ajuste de ph; uso para tratar el ojo.

Info

Publication number
CL2009000573A1
CL2009000573A1 CL2009000573A CL2009000573A CL2009000573A1 CL 2009000573 A1 CL2009000573 A1 CL 2009000573A1 CL 2009000573 A CL2009000573 A CL 2009000573A CL 2009000573 A CL2009000573 A CL 2009000573A CL 2009000573 A1 CL2009000573 A1 CL 2009000573A1
Authority
CL
Chile
Prior art keywords
polysorbate
chlorides
preservative
eye
contain
Prior art date
Application number
CL2009000573A
Other languages
English (en)
Spanish (es)
Inventor
Bhagwati P Kabra
Ruma Sarkar
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of CL2009000573A1 publication Critical patent/CL2009000573A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
CL2009000573A 2008-03-11 2009-03-11 Composicion farmaceutica inyectable intraocular en forma de suspension acuosa que no contiene preservante, que consiste de acetonido de triamcinolona, carboximetilcelulosa de sodio, 0,002-0,02% de polisorbato 80, cloruros para ajustar la tonicidad, agente tamponante, agua y agente de ajuste de ph; uso para tratar el ojo. CL2009000573A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3545908P 2008-03-11 2008-03-11

Publications (1)

Publication Number Publication Date
CL2009000573A1 true CL2009000573A1 (es) 2010-01-04

Family

ID=40548758

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000573A CL2009000573A1 (es) 2008-03-11 2009-03-11 Composicion farmaceutica inyectable intraocular en forma de suspension acuosa que no contiene preservante, que consiste de acetonido de triamcinolona, carboximetilcelulosa de sodio, 0,002-0,02% de polisorbato 80, cloruros para ajustar la tonicidad, agente tamponante, agua y agente de ajuste de ph; uso para tratar el ojo.

Country Status (21)

Country Link
US (3) US8128960B2 (enExample)
EP (1) EP2262506B1 (enExample)
JP (1) JP5581227B2 (enExample)
KR (1) KR101555293B1 (enExample)
CN (1) CN101959519B (enExample)
AR (1) AR070824A1 (enExample)
AU (1) AU2009223649B2 (enExample)
BR (1) BRPI0909630B8 (enExample)
CA (1) CA2717605C (enExample)
CL (1) CL2009000573A1 (enExample)
DK (1) DK2262506T3 (enExample)
ES (1) ES2471122T3 (enExample)
MX (1) MX2010009974A (enExample)
PL (1) PL2262506T3 (enExample)
PT (1) PT2262506E (enExample)
RU (1) RU2481842C2 (enExample)
SI (1) SI2262506T1 (enExample)
TW (1) TWI468165B (enExample)
UY (1) UY31699A1 (enExample)
WO (1) WO2009114521A1 (enExample)
ZA (1) ZA201005839B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
JP5581227B2 (ja) * 2008-03-11 2014-08-27 アルコン リサーチ， リミテッド 硝子体内注射のための低粘度、高凝集トリアムシノロンアセトニド懸濁剤
WO2010074961A1 (en) * 2008-12-22 2010-07-01 Alcon Research, Ltd. Compositions of topical ocular solutions to deliver effective concentrations of active agent to the posterior segment of the eye
JP5996544B2 (ja) 2010-10-15 2016-09-21 クリアサイド・バイオメディカル・インコーポレーテッドＣｌｅａｒｓｉｄｅ Ｂｉｏｍｅｄｉｃａｌ Ｉｎｃｏｒｐｏｒａｔｅｄ 眼球アクセス用装置
CN102008488B (zh) * 2010-11-24 2012-10-10 广州固志医药科技有限公司 一种曲安奈德眼用制剂及其制备方法
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
BR112015010566A2 (pt) * 2012-11-08 2017-07-11 Clearside Biomedical Inc métodos e dispositivos para o tratamento de doenças oculares em indivíduos humanos
EA032039B1 (ru) 2013-05-03 2019-03-29 Клиасайд Байомедикал, Инк. Устройство для проведения глазной инъекции
US10188550B2 (en) 2013-06-03 2019-01-29 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
RU2710491C2 (ru) 2014-06-20 2019-12-26 Клиасайд Байомедикал, Инк. Устройство для инъекции лекарственного средства в глазную ткань и способ инъекции лекарственного средства в глазную ткань
US9694145B1 (en) 2016-03-29 2017-07-04 Joseph Onorato Auto-injector systems and method for delivering cyst medication on demand
WO2017192565A1 (en) 2016-05-02 2017-11-09 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
CA3072847A1 (en) 2016-08-12 2018-02-15 Clearside Biomedical, Inc. Devices and methods for adjusting the insertion depth of a needle for medicament delivery
US12090294B2 (en) 2017-05-02 2024-09-17 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
WO2019136512A1 (en) * 2018-01-10 2019-07-18 Eye Co Pty Ltd Medical device and pharmaceutical composition for treatment of an eye disease or condition
USD893715S1 (en) 2018-11-06 2020-08-18 Joseph Onorato Measurement guide for a cyst, lesion or skin disorder
TW202103707A (zh) * 2019-04-16 2021-02-01 美商克利爾斯德生物醫學公司 注射用安西諾隆（ｔｒｉａｍｃｉｎｏｌｏｎｅ）調配物
US10799481B1 (en) 2019-05-06 2020-10-13 Rvl Pharmaceuticals, Inc. Compositions and methods for treating ocular disorders
CN114010593A (zh) * 2021-11-23 2022-02-08 莱默(北京)药业科技有限公司 一种曲安奈德混悬注射液及制备方法
CN115969784B (zh) * 2022-12-26 2025-10-21 昆明积大制药股份有限公司 曲安奈德注射液的制备方法
WO2025114562A1 (en) * 2023-11-30 2025-06-05 Institut National de la Santé et de la Recherche Médicale Intravitreal spironolactone suspension

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962430A (en) * 1974-08-07 1976-06-08 Merck & Co., Inc. Sterilization of solid non-electrolyte medicinal agents employing sodium chloride
US4370325A (en) * 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
US4432964A (en) * 1981-08-24 1984-02-21 Alza Corporation Topical composition containing steroid in two forms released independently from polymeric carrier
US5164190A (en) * 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
WO1995003807A1 (en) 1993-07-27 1995-02-09 The University Of Sydney Treatment of age-related macular degeneration
WO1996020712A1 (en) 1994-12-30 1996-07-11 American Home Products Corporation Clear non-alcoholic hydrocortisone solutions
KR20010071827A (ko) 1998-07-10 2001-07-31 앤더슨 데릭 제이. 반점성망막 퇴행에서 신혈관 신생의 예방치료
AR026073A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
AUPQ496500A0 (en) 2000-01-06 2000-02-03 University Of Sydney, The Kit
US6395294B1 (en) 2000-01-13 2002-05-28 Gholam A. Peyman Method of visualization of the vitreous during vitrectomy
US6656505B2 (en) * 2000-07-21 2003-12-02 Alpharma Uspd Inc. Method for forming an aqueous flocculated suspension
WO2002015878A1 (fr) * 2000-08-25 2002-02-28 Senju Pharmaceutical Co., Ltd. Preparations en suspension aqueuse
EP1414466B1 (en) * 2001-07-09 2009-08-19 CombinatoRx, Incorporated Combinations for the treatment of inflammatory disorders
US20030129242A1 (en) 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
CA2516782A1 (en) 2003-02-20 2004-09-02 Alcon, Inc. Use of steroids to treat ocular disorders
US20040186084A1 (en) 2003-03-21 2004-09-23 Akorn, Inc. Triamcinolone formulations and methods for their preparation and use
KR20060095974A (ko) * 2003-09-23 2006-09-05 알콘, 인코퍼레이티드 트리암시놀론 아세토나이드 및 아네코르타브 아세테이트주사용 제제
US20060141049A1 (en) 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
KR20060123493A (ko) * 2003-12-23 2006-12-01 알자 코포레이션 제어된 전달을 위한 약물 조성물의 용해도를 증가시키는방법 및 제형
DE602005011928D1 (de) 2004-01-20 2009-02-05 Allergan Inc Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon-acetonid und hyaluronsäure
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
MXPA06013870A (es) 2004-05-31 2007-04-25 Senju Pharma Co Agente para visualizar tejido transparente.
US20060089590A1 (en) 2004-10-27 2006-04-27 John Higuchi Methods and devices for sustained in-vivo release of an active agent
EP1827378A2 (en) 2004-11-17 2007-09-05 Government of The United States of America, as represented by Secretary, Department of Health and Human Services Steroid formulation and methods of treatment using same
KR20070104645A (ko) * 2005-02-18 2007-10-26 산텐 세이야꾸 가부시키가이샤 스테로이드 화합물의 부작용 경감 또는 회피 방법
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
ITRM20050547A1 (it) 2005-11-04 2007-05-05 Sooft Italia S R L Gel oftalmico composto da triamcinolone acetonide e da un polimero poliacrilico.
JP5581227B2 (ja) * 2008-03-11 2014-08-27 アルコン リサーチ， リミテッド 硝子体内注射のための低粘度、高凝集トリアムシノロンアセトニド懸濁剤

Also Published As

Publication number Publication date
US20090233890A1 (en) 2009-09-17
RU2481842C2 (ru) 2013-05-20
WO2009114521A1 (en) 2009-09-17
ZA201005839B (en) 2011-10-26
AR070824A1 (es) 2010-05-05
DK2262506T3 (da) 2014-06-10
BRPI0909630A2 (pt) 2015-09-22
PL2262506T3 (pl) 2014-09-30
UY31699A1 (es) 2009-05-29
EP2262506B1 (en) 2014-05-07
MX2010009974A (es) 2010-09-30
BRPI0909630B1 (pt) 2019-03-26
ES2471122T3 (es) 2014-06-25
CN101959519A (zh) 2011-01-26
JP2011513492A (ja) 2011-04-28
US20120115829A1 (en) 2012-05-10
CA2717605A1 (en) 2009-09-17
PT2262506E (pt) 2014-06-24
JP5581227B2 (ja) 2014-08-27
TWI468165B (zh) 2015-01-11
CA2717605C (en) 2012-05-15
KR20100127267A (ko) 2010-12-03
RU2010141542A (ru) 2012-04-20
US8211880B2 (en) 2012-07-03
CN101959519B (zh) 2013-03-20
US20120116216A1 (en) 2012-05-10
KR101555293B1 (ko) 2015-10-06
EP2262506A1 (en) 2010-12-22
TW200940071A (en) 2009-10-01
HK1146464A1 (en) 2011-06-10
BRPI0909630B8 (pt) 2021-05-25
AU2009223649B2 (en) 2013-08-29
AU2009223649A1 (en) 2009-09-17
US8128960B2 (en) 2012-03-06
SI2262506T1 (sl) 2014-07-31

Similar Documents

Publication Publication Date Title
CL2009000573A1 (es) Composicion farmaceutica inyectable intraocular en forma de suspension acuosa que no contiene preservante, que consiste de acetonido de triamcinolona, carboximetilcelulosa de sodio, 0,002-0,02% de polisorbato 80, cloruros para ajustar la tonicidad, agente tamponante, agua y agente de ajuste de ph; uso para tratar el ojo.
MX2020005942A (es) Delgada pelicula oral con alta carga de agente activo.
MX2010002247A (es) Uso de una combinacion de hesperidina y de un microorganismo para influir en la funcion de barrera de la piel.
CL2013002467A1 (es) Composición oftálmica que comprende al menos 0,67% pero no más de 1,0% p/v de olopatadina disuelta en solucion, peg con un peso molecular de 300 a 500, polivinilpirrolidona, hidroxialquil ß-ciclodextrina, hidroxialquil ?-ciclodextrina o su combinación y cloruro de benzalconio; gotario que comprende a la composición oftálmica; y su uso en el tratamiento de la conjuntivitis alérgica ocular.
CO6650415A2 (es) Nuevas formas de dosificacion de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidoes de xantina oxidasa
CR11167A (es) Uso de homo y copolimeros para la estabilizacion de formulaciones de principios activos
WO2009028495A1 (ja) 真菌性皮膚炎用剤
CL2010001406A1 (es) Composicion farmaceutica oftalmica que comprende povidona yodada, y un compuesto antiinflamatorio esteroidal, un compuesto antiinflamatorio no esteroidal, un antibacteriano, un antialergico o un compuesto antiglaucoma; y metodo para preservar la composicion.
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
AR082381A1 (es) Composicion acuosa que contiene bromhexina
NZ708247A (en) Hyaluronic acid based formulations
SI1933809T1 (sl) Sestavki za mazalno dajanje
CL2018001420A1 (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853)
IT1392903B1 (it) Composizione comprendente un'associazione di principi attivi per uso nel trattamento topico della calvizie
AR081520A1 (es) Composicion farmaceutica que comprende una dispersion solida de tacrolimus en un vehiculo
CO6280502A2 (es) Una composicion farmaceutica
GEP20115348B (en) Pharmaceutical composition for treating burns (variants) and methods for the production thereof (variants)
ES2487496T3 (es) Agente para aliviar el síndrome metabólico
BR112012015449A2 (pt) suspensão de monoidrato de calcipotriol, monoidrato de calcipotriol, processo para preparar nanocristais de monoidrato de calcipotriol, e, composição farmacêutica
NO20091517L (no) Emulsjon
CL2008002758A1 (es) Composicion que comprende al menos un principio activo laxante y al menos un principio activo antiespumante; uso para el tratamiento del estrenimiento.
TR201101807T2 (tr) Rosuvastatin kalsiyumun farmasotik bileşimleri
CL2011000174A1 (es) Composicion que contiene al menos quitosano, un hidroxipropil quitosano y/o una sal fisiologicamente aceptable y al menos una amida lineal de acido alquilc6-12-dicarboxilico y/o una sal fisiologicamente aceptable, util en el tratamiento de la rosacea y telangiectasia.
EA201000330A1 (ru) Способ повышения значения ph кислых водоемов
CL2012001545A1 (es) Composiciones farmacéuticas acuosas que comprende un éster de un prostanoide, un ácido carboxílicoentre 1,2,1,6% de fosfato dibásico de sodio, cloruro de sodio, un agente de solubilización, y el resto de agua, con un ph va de 4 a 8; uso en desordenes oculares como glaucoma, retinopatia diabetica, uveitis, entre otras.